6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Program Director: Fredrick Hagemeister, MD, Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

July 15, 2017–Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, TX 77030; Phone: 713-796-0080

Jointly Provided by
The A. Webb Roberts Center for CME of Baylor Scott & White Health, CancerNet and American Health Resource, Inc

Educational Grants
Amgen Inc.
Merck Sharp & Dohme Corp.
AbbVie Inc.
Gilead Sciences Inc.
Novartis Pharmaceuticals Corporation
Pfizer
Millennium Pharmaceuticals, Inc.

For online registration and more information visit: www.cancernetus.com

Target Audience
This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Statement of Need/Program Overview
This symposium is intended to improve care of patients with Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Learning Objectives
- Evaluate the prognostic markers, risk stratification and the impact on novel therapies for Hodgkin lymphoma
- Interpret and adapt the data from recent clinical trials on immunotherapy options for Hodgkin lymphoma
- Identify the treatment options for diffuse large B-cell lymphoma (DLBCL)
- Cite the treatment options for follicular lymphoma (FL)
- Apply the treatment options for chronic lymphocytic lymphoma (CLL)
- Identify the treatment options for mantle cell lymphoma (MCL)
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia (ALL)
- Evaluate the gene–gene co-occurrences and how compound genotypes are related to novel therapeutic options based clinical outcomes in patients with acute myeloid leukemia (AML)
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of chronic myelogenous leukemia (CML)
- Discuss the time-based response milestones and monitoring in patients with CML

**Faculty**

Jorge Cortes, MD, Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX

Nathan Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Fredrick B. Hagemeister, MD, Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elisabet E. Manasanch, MD, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Robert Orlowski, MD, PhD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael Wang, MD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

William G. Wierda, MD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

**Registration Fee**

Registration fee partially covers continental breakfast, lunch and syllabus book

<table>
<thead>
<tr>
<th></th>
<th>Early Registration Fee (Up to 6/30/17)</th>
<th>Discounted Registration Fee (7/1/17 to 7/7/17)</th>
<th>Regular Registration Fee (7/8/17 to 7/15/17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$100.00</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Registered Nurses</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Nurse Practitioners</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Physician Assistants</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Pharmacists</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Fellows</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>*Industry</td>
<td>$350.00</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
</tbody>
</table>

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: □ MC □ Visa □ Discover □ Check
Credit Card Number ___________________________ Expiration Date ___________________________ Email ___________________________

Pharmacist e-profile NABP# ___________________________ Pharmacist DOB (MMDD) ___________________________

Signature ___________________________

†as given on the monthly credit card statement

No refund. Substitution is allowed.

Register online at www.cancernetus.com
Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057.

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. For questions please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The A. Webb Roberts Center for CME of Baylor Scott & White Health designates this educational activity for a maximum of 6.5AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement
American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 6.5 contact hours. Please check with licensing board to verify credits can be claimed in your state.

Pharmacist Continuing Education
Accreditation Statement
American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This activity provides 6.5 contact hours (0.65CEUs) - Application-based credits
ACPE Universal Activity Number: 0280-9999-17-064-L01-P

Participant Requirements for Credit (Nurses and Pharmacists):
• Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
• Participants can earn Continuing Education credits for this program by logging onto the website https://ce.ahrevents.com/ and completing the session evaluation form for sessions attended.
  o Nurses: After completion of the evaluation, certificate of credit can be printed.
  o Pharmacists: After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.
  * Only Certificates of Credit issued from CPE Monitor are valid in the US
  * CPE Monitor will not accept credits after 60 days from the session date
• All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation: All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Breakfast and Registrations</td>
<td></td>
</tr>
<tr>
<td>7:55 AM</td>
<td>Welcome and Introductions</td>
<td>Fredrick B. Hagemeister, MD</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Overview of Diagnosis and Novel Treatment Options in the Management of Hodgkin Lymphoma (HL)</td>
<td>TBD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Overview of Immunotherapy Options for HL</td>
<td>Fredrick B. Hagemeister, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Overview of Treatment Options for Diffuse Large Cell Lymphoma (DLCL)</td>
<td>Fredrick B. Hagemeister, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Overview of Treatment Options for Follicular Lymphoma (FL)</td>
<td>Nathan Fowler, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Panel Discussion and Case Presentation</td>
<td>Fredrick B. Hagemeister, MD/Nathan Fowler, MD</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Overview of Treatment Options for Mantle Cell Lymphoma (MCL)</td>
<td>Michael Wang, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Overview of Treatment Options for Chronic Lymphocytic Leukemia (CLL)</td>
<td>William Wierda, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>An Overview on Systemic Therapy for Patients with Newly Diagnosed Active Multiple Myeloma (MM)</td>
<td>Elizabet Manasanch, MD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Outline the Selection, Sequencing and/or Combination of Novel Therapies for Patients with Relapsed/ refractory MM</td>
<td>Robert Orlowski, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Panel Discussion and Case Presentation</td>
<td>Michael Wang, MD/William Wierda, MD/Elizabet Manasanch, MD/Robert Orlowski, MD</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/Refractory Patients with ALL</td>
<td>Elias Jabbour, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>How Gene–gene Co-occurrences and Compound Genotypes are Related to Novel Therapies Based Clinical Outcomes in Patients with AML</td>
<td>Jorge Cortes, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Response Assessment and Management of Tyrosine Kinase Inhibitors Resistance in the Management of Chronic Myelogenous Leukemia (CML)</td>
<td>Elias Jabbour, MD</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>Understanding of Time-based Response Milestones and Monitoring in Patients with CML</td>
<td>Jorge Cortes, MD</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Panel Discussion and Case Presentation</td>
<td>Elias Jabbour, MD/Jorge Cortes, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Closing Remarks and Adjourn</td>
<td>Fredrick B. Hagemeister, MD</td>
</tr>
</tbody>
</table>